Anxiety · Non-Pharmacological InterventionTrial Updateclinicalmid-term

Study Evaluates VR Device for Anxiety and Pain in Interventional Radiology

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 12:31:45 PM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The HYPNO-VR study could redefine pain and anxiety management in interventional radiology by validating VR as a non-pharmacological alternative. Success in this trial may prompt pharma companies to reevaluate their strategies and consider integrating VR technologies into their offerings. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 6 ranked evidence items (2 high-relevance).

Strategic Assessment

Pharma and biotech companies may need to consider VR technologies in their pain management strategies and explore partnerships or developments in this area. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 1 competitive items passed relevance filtering for HYPNO-VR.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). If successful, this study could position VR as a viable alternative to pharmacological interventions, impacting the market for anxiety and pain management solutions.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The outcomes of this trial may influence regulatory perspectives on non-pharmacological interventions, potentially leading to new guidelines or approvals for VR devices in clinical settings.

Key Risks

Elevated medium regulatory exposure for HYPNO-VR could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If VR is proven effective, it could disrupt existing pain management markets, potentially reducing reliance on traditional pharmacological treatments and altering market share dynamics.
Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.
Pharma and biotech companies may need to consider VR technologies in their pain management strategies and explore partnerships or developments in this area.

What Would Change This Assessment

This becomes more urgent if Monitor results from the trial, particularly the primary outcomes related to anxiety and pain reduction, as well as patient satisfaction metrics.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Early Alert: Positive Pressure Breathing Device Issue from Baxter
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
A Study of the Impact of Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.
ClinicalTrials.govmedium relevance
Entity match (hypno-vr)
FDA document
View source
Take5Care+: A Self-management Educational Intervention
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Endometrial Cavity After Conservative Management of PAS Patients by Hysteroscopy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hybrid Type 1 Trial of Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Use
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

HYPNO-VR
pain management solutions

Commercial impact

medium

If VR is proven effective, it could disrupt existing pain management markets, potentially reducing reliance on traditional pharmacological treatments and altering market share dynamics.

Regulatory impact